DIA global headquarters will host 18 leaders from the State Food and Drug Administration of China (SFDA). The SFDA delegation is comprised of leaders from different provinces of China as well as four individuals from the central office in Beijing. Their expertise includes drug registration and the center of control testing labs.
Prior to their arrival at DIA, the group participated in a 10-day regulatory affairs training at Yale University’s School of Public Health. Since completing the program earlier this week, the delegation has been visiting various organizations such as the NJ FDA Field Office, Novartis, the University of Sciences Philadelphia, and the United States Pharmacopeia (USP). SFDA participants include:
“DIA is a global community that shares knowledge, cultivates relationships, and facilitates dialogue among regulators across and within all geographic regions,” says Paul Pomerantz, DIA Worldwide Executive Director.” We are pleased to welcome representatives from SFDA to our global headquarters to explore how our organizations can continue to work together to educate our industry about reporting, compliance and other requirements and developments around the world.”
In addition, three executive team members from the Sino-American Pharmaceutical Professionals Association of Greater Philadelphia (SAPA GP) will be in attendance.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.